EGFR and cancer: For instance, to limit the above-mentioned off-target side effects, neutralizing antibodies could be developed against aberrant core fucosylation of pro-invasive/pro-metastatic glycoproteins such as integrin αvβ5 or IL6ST identified in this study or cancer growth-promoting cell surface epidermal growth factor receptor [16].